Botulinum toxin A (BoNT-A) has become the first-line therapy in cervical dystonia (CD), blepharospasm and spasticity. However, the current guidelines for the clinical use of BoNT-A are based on data published more than 20 years ago and patient satisfaction with current treatment regimens is low. There is a striking difference between the injection intervals given in everyday clinical practice and the injection intervals preferred by patients. Recent data have indicated that shorter injection intervals may improve overall patient satisfaction since re-emergence of symptoms could be prevented. Three double-blind studies have demonstrated that incobotulinumtoxin A (incoBoNT-A) is suitable for use in a flexible, patient-centric approach in blepharospasm and CD, with injection intervals starting from 6 weeks. The efficacy, tolerability and safety of this regime were excellent. There is a need to optimise and individualise the treatment using the three available formulations of BoNT-A, as well as to define parameters for switching between the formulations.
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Dr Jacinto began with the Institute of Medicine definition of patientcentric care that is respectful of and responsive to individual patient preferences, requirements and values, ensuring that patient values guide all clinical decisions. 2 He proceeded to discuss the evaluation of patient-centric care in spasticity and dystonia. There is a need to establish what patients want and need, in addition to what healthcare professionals consider therapeutic goals and to provide a tool for to evaluate treatment. 3, 4 Many people consider that there is a discrepancy between patients' and doctors' evaluations.
A recent online survey (n = 969) conducted in the US and EU showed that there is a need for an improvement in CD management in terms of patient satisfaction. 5 A patient-centric approach may necessitate a re-evaluation of how ambitious we should be for each treatment cycle in terms of number of muscles, doses and adjunctive treatments.
Individual perception is very important in assessing treatment effect; the response to BoNT-A is multidimensional, and may be measured in terms of magnitude, duration, waning of effect, tolerability and safety.
It is therefore difficult for the patients to accurately interpret treatment response. Furthermore, the response is not immediate, leading to memory bias. Therefore, it is important to evaluate treatment in an individualised manner and to manage patient's expectations. 6 In a 2005 study of 78 patients (mean age 54 years, 65 % female) with CD, patients' satisfaction with long-term BoNT-A treatment (median 5.5 years, range 1.5-10) was evaluated on a seven-point scale ranging from excellent to worsening. The independent evaluations of the treating neurologists broadly correlated with the patient's scores but differed in the excellent category (9 % of patients versus 17 % neurologists). 7 Recommendations in national guidelines generally evaluate the effectiveness of BoNT-A treatment for spasticity in terms of improvement of the modified Ashworth scale. [8] [9] [10] Treatment effect is usually measured around the time of maximum effect (between 4 and 6 weeks after injection) and after 12 weeks (termination of the study or re-injection).
There is no measurement of treatment effect in the time between the peak effect and the usual time point of re-injection. In addition, functional improvement is usually not adequately measured in most studies, partly due to the lack of sensitive assessment scales that relate to real-life tasks. Duration is typically not reported, since a routine injection interval is used (and/or single injection). Doses and injection patterns are predefined in most study protocols; studies are generally constrained in this aspect by the need to serve regulatory purposes. Patient-reported outcomes are usually limited to the Global Assessment of Efficacy and Tolerability at the end of the study (mostly single-injection studies).
Sometimes the Disability Assessment Scale (DAS), and, more recently, the Goal Attainment Scale (GAS) have been used. [8] [9] [10] [11] [12] [13] [14] The interval between injections is a factor that has not been widely debated. Many reviews give no specific recommendations on injection interval and state that more research is required. [9] [10] [11] [12] 15 The French guidelines, however, recommend a 3-month interval although they agree that long-term studies are missing. 13 The UK guidelines state that although patients may become biologically resistant to
BoNT-A as a result of antibody formation, it is rarely reported in practice.
They recommend a review at three to four months post-injection, when the effect of the toxin is likely to have worn off. 8 Current product labelling of BoNT-A formulations recommends injection intervals of ≥10 weeks 16 (incobotulinumtoxinA in Europe only) to ≥12 weeks [17] [18] [19] [20] [21] for the treatment of CD. For spasticity, the current standard of care is injection intervals of at least 3 months. [22] [23] [24] However, some patients may experience re-emergence of symptoms before the next dose is included. 25 In the survey in spasticity, patients receiving aboBoNT-A, incobotulinumtoxinA (incoBoNT-A, Xeomin ® , Merz Pharmaceuticals) and onaBoNT-A were included. 26 Interviews were conducted either at 7-8 weeks or 9-10 weeks after the patient's last injection session; these time frames were considered to allow sufficient time for the BoNT-A to confer peak clinical effects.
In the CD survey, patients (n=136) usually received BoNT-A treatment at intervals of every 9-10 weeks (4.4 %), every 11-12 weeks (42.7 %), every 13-14 weeks (27.2 %), every 15-16 weeks (10.3 %) or >17 weeks (15.4 %). The mean (standard deviation [SD] ) interval between injection sessions was 14.0 (3.7) weeks. 25 Patient satisfaction tended to follow the peak and waning of treatment effect. Satisfaction was greatest when patients were recalling the time of peak treatment effect. At this time point, the majority of patients (77.5 %) were very satisfied with treatment. Fewer patients were very satisfied at the time of the interview (7-10 weeks after the previous injection session; 50.7 %), and fewer again recalled being very satisfied just prior to the last injection session (13.7 %), when the effects of the previous dose would be diminishing. 25 At this time point, 39.2 % of patients reported not being satisfied at all. When asked for their preferred injection interval preferences, patients' responses varied, with a mean preferred injection interval of 12.9 weeks, although 46 % of patients would have preferred intervals of ≤10 weeks. Around half of patients stated that, given the choice, they would have a re-injection on the day of the interview (31.6 % somewhat; 22.1 % very much). 25 In the spasticity survey (n=79), when asked about the interval at which they normally receive injection sessions, 54.5 % of patients stated they received injections at intervals of more than 12 weeks. 26 When asked about their preference for injection intervals, 78.9 % stated that they EuropEaN NEurological rEviEw would prefer an interval shorter than 12 weeks, and 43.4 % would prefer intervals of 10 weeks or less. The majority of patients stated a preference for re-injection on the day of their interview (36.7 % somewhat; 36.7 % very much so). Interviews were conducted 7-10 weeks after the most recent injection. As seen in the CD survey, patient satisfaction tended to follow the peak and waning of treatment effect. Satisfaction was greatest when patients recalled the time of peak treatment effect. For this time point, the majority of patients (68.2 %) were very satisfied with treatment. Few patients recalled being very satisfied just prior to the last injection session (9.1 %), when the effects of the previous dose would be diminishing. There was a striking difference between the injection intervals given (54.5 % >12 weeks) and the injection intervals preferred (78.9 preferred an interval of <12 weeks, see Figure 1 ). The majority of patients stated that, given the choice, they would have a re-injection on the day of their interview (31.6 % somewhat; 22.1 % very much so). 26 In summary, the mean BoNT-A injection interval for patients is approximately 14 weeks. However, nearly the half of patients with CD and spasticity would prefer intervals of 10 weeks or less. Patient satisfaction levels generally follow the onset, peak and trough of clinical effect. Satisfaction was lowest just prior to the next injection session, which may have been due to symptom re-emergence. Shorter injection intervals may therefore improve overall patient satisfaction. ■ Dr Jankovic began by reinforcing the conclusion of the previous presentation: that some patients might benefit from more frequent injections than the currently recommended minimum injection intervals of ≥12 weeks, which is based on data published more than 20 years ago. 1 Three recent double-blind clinical trials have, for the first time, investigated on-demand, flexible injection intervals to allow treatment individualisation. [27] [28] [29] In these trials, patients were able to visit the physician when they felt a repeat injection was necessary. The physician then objectively verified the need for a repeated injection, and retreated where indicated. In two trials, the study design was a randomised, placebo-controlled, double-blind main period, in which patients received a single injection of placebo or incoBoNT-A, 30, 31 and in one study this was followed by an open-label extension period comprising a maximum of five injection sessions at ≥6-week intervals (the maximum study duration was 88 weeks for an individual patient; see Figure 2) . 27, 28 The third study evaluated the safety of two different doses of incoBoNT-A in a randomised, double-blind fashion as an extension to the CD placebocontrolled study. The study permitted flexible injection intervals as short as 6 weeks if patients had a clinical need for re-injection. Important inclusion criteria were Jankovic Rating Scale (JRS) 32 severity subscore ≥2 in blepharospasm and Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) 33 total score ≥20 in CD.
The mean study duration of the blepharospasm extension study was In the CD studies, patients (n=219 completing the main randomised, double-blind, placebo-controlled period; 214 in the extension randomised, double-blind study) were randomised to at the beginning of the studies to 240 U or 120 U (or placebo in the main phase). Evaluation of TWSTRS scores showed a significant improvement over the extension period (see Figure 3) . 27 At every contact, patients were questioned about AEs; the most frequently reported treatment related AEs were dysphagia, injection-site pain, neck pain, muscular weakness and musculoskeletal pain (see Table 1 ). No serious treatment-related AEs were reported.
There was a wide range of injection intervals: ≤10 weeks (22.5 %), >10 to ≤12 weeks (24.6 %), >12 to ≤14 weeks (19.4 %) and >14 weeks (33.5 %) No differences were seen in the overall occurrence of AEs between the injection groups (p=0.1117). 27 An additional safety analysis in the CD study evaluated the incidence of dysphagia, muscular weakness, neck pain and injection site pain according to injection interval. The frequency of AEs per injection session was lower in the 6-7 week injection interval than the AE rate A. 
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Professor Albanese began by summarising the evidence-based reviews that have resulted in BoNT-A becoming the first-choice treatment for most types of focal dystonia. [34] [35] [36] BoNT-A has been given an American Academy of Neurology level A recommendation in this indication. 37 BoNT-A provides dose-related temporary denervation, targets specific muscles, maintains strength in non-treated muscles, corrects deformity without generating generalised weakness and reduces pain independently of muscle tone. Treating more severely dystonic muscles may also quell hyperactivity in other involved muscles. 38 In addition, results are long lasting. 39 However, when using a patient-centric approach, we need to guarantee reproducible results with guaranteed safety and tolerability. AEs have been mild and transient; some dysphagia and injection pain, blurred vision and muscle weakness has been reported. 1, 31, [42] [43] [44] Three comparative studies have also been reported in CD. In a study designed to establish whether a ratio of 1:3 aboBoNT-A: onaBoNT-A is equivalent, the mean time to retreatment was 3 days shorter in the aboBoNT-A group than in the onaBoNT-A group (not significant). 45 In another study, higher improvement of Tsui scores (primary outcome criteria) was seen with aboBoNT-A compared with onaBoNT-A (ratios of 1:3 or 1:4 were used). No significant difference was seen between the 1:3 and 1:4 groups, and more AEs were reported with aboBoNT-A, the most frequent being dysphagia (3 % with onaBoNT-A, 15.6 % with aboBoNT-A 1:3, and 17.3 % with aboBoNT-A 1:4), but the effect was minor. 46 In the first comparative study of onaBoNT-A and incoBoNT-A in CD, a 1:1 ratio was used. No difference was seen between the two groups in the mean change from baseline in TWSTRS severity score 1-month post injection. 47 In terms of blepharospasm, the use of BoNT-A is based on four placebo-controlled trials. 30, 32, 44, 48 Three comparative studies have also been reported, and all show no differences in efficacy and safety outcomes between onaBoNT-A and incoBoNT-A. [49] [50] [51] Using a 4:1 ratio for aboBoNT-A and onaBoNT-A, similar results were obtained for the two treatments, suggesting that this conversion factor is a good estimate of their comparative clinical potencies. 52 In addition, numerous placebo-controlled trials support the use of all three formulations of BoNT in spasticity. [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] In terms of switching from one product to another, while several studies have shown that a 1:1 ratio of onaBoNT-A: incoBoNT-A is appropriate for clinical dose conversion, 41, [68] [69] [70] [71] [72] [73] [74] the potency of aboBoNT-A relative to onaBoNT-A has been estimated to range from 1:2 to 1:11. 75, 76 A randomised controlled trial suggested a ratio of 1:3 but the products are still not equivalent at this ratio. 77 Recent studies suggest that 1:4 may be more appropriate. 73, 78 AE rates are comparable for all three products with conversion ratios of 1:1 for onaBoNT-A and incoBoNT-A; and 1:4 for incoBoNT-A/onaBoNT-A and aboBoNT-A. 68, 79 In summary, in terms of a patient-centric approach, all three BoNT-A formulations have been shown to be effective and well tolerated in a range of indications but the switch from aboBoNT-A to onaBoNT-A or incoBoNT-A is more difficult due to the variable relative potency. ■
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Istituto Nazionale Neurologico Carlo Besta, Milan, Italy in longer injection intervals and in comparable single injection trials. 29 Investigators rated treatment tolerability for each injection cycle at the subsequent injection visit or at the TTV (up to 20 weeks after the last injection). Using the IGAT scale, tolerability was rated 'good' or 'very good' for the vast majority of patients (≥91.5 % for all treatments) in both dose groups. 27 Antibody assays were performed at screening, control visit day 6, final visit of main phase, reinjection visits and TTV. These were assessed by a validated fluorescence immunoassay for antibodies (FIA-AB).
Positive FIA-AB samples were tested with a validated mouse ex vivo hemidiaphragm assay (HDA). No patients had developed neutralising antibodies (nAbs) at study termination, including those patients that required reinjection at week 6. It should be noted that 2.6 % of the onaBoNT-A pre-treated patients had nAbs at screening. 28, 29 In conclusion, incoBoNT-A was well tolerated and effective over the study period in the treatment of blepharospasm and CD after a total of maximum six injections. Injections administered in shorter injection intervals were as well tolerated as those given in long-injection intervals. No cumulative AEs were reported with repeated doses and the majority of AEs were mild or moderate and temporary. The clinical study data support the relative safety of short-injection intervals for incoBoNT-A. ■
The symposium was closed with the conclusion that currently available BoNT-A formulations are appropriate first-line therapies in CD, blepharospasm and spasticity. However, shorter injection intervals may improve overall patient satisfaction since re-emergence of symptoms could be prevented. Recent data have shown that incoBoNT-A is suitable for use in a patient-centric approach with injection intervals starting from 6 weeks, with excellent efficacy and tolerability. This has not been investigated in the other formulations. Concerns over an increased risk of nAbs with short injection intervals were largely based on an early study with the original formulation of onaBoNT-A, which showed a much higher incidences of nAbs. In the recent studies involving incoBoNT-A nAbs were not detected in any patients, despite the fact that incoBoNT/a have been used in intervals as short as 6 weeks. Further research is warranted to determine parameters for optimising and individualising the treatment using the three available formulations of BoNT-A. Practicalities for incorporation of a flexible dosing regimen should be explored in clinical practice, and future design of studies should take into account patient needs. ■
Summary and Concluding Remarks
